Elicio Therapeutics (ELTX) Debt to Equity (2020 - 2026)

Elicio Therapeutics (ELTX) has 4 years of Debt to Equity data on file, last reported at -$6.59 in Q1 2026.

• For the quarter ending Q1 2026, Debt to Equity changed N/A year-over-year to -$6.59; the trailing twelve-month figure through Mar 2026 stood at -$6.59 (changed N/A YoY), and the FY2025 full-year result was $5.75, up 424.67% from the prior year.
• Debt to Equity for Q1 2026 stood at -$6.59, down from $5.75 in the prior quarter.
• Across five years, Debt to Equity topped out at $5.75 in Q4 2025 and bottomed at -$6.59 in Q1 2026.
• The 3-year median for Debt to Equity is $2.55 (2025), against an average of $1.0.
• Peak annual rise in Debt to Equity reached 424.67% in 2025, while the deepest fall reached 424.67% in 2025.
• A 3-year view of Debt to Equity shows it stood at -$1.77 in 2024, then jumped by 424.67% to $5.75 in 2025, then tumbled by 214.67% to -$6.59 in 2026.
• The last three Debt to Equity figures came in at -$6.59 (Q1 2026), $5.75 (Q4 2025), and $2.55 (Q3 2025), per Business Quant data.

Peer Comparison